Literature DB >> 17191111

Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes.

Y Jinnouchi, S Yamagishi, M Takeuchi, S Ishida, Y Jinnouchi, J Jinnouchi, T Imaizumi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17191111     DOI： 10.1007/s10238-006-0115-6

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN： 1591-8890            Impact factor:   3.984


× No keyword cloud information.
  20 in total

1.  Statins stimulate the production of a soluble form of the receptor for advanced glycation end products.

Authors:  Patricia Quade-Lyssy; Anna Maria Kanarek; Markus Baiersdörfer; Rolf Postina; Elzbieta Kojro
Journal:  J Lipid Res       Date:  2013-08-21       Impact factor: 5.922

2.  An alpha-glucosidase inhibitor, acarbose treatment decreases serum levels of glyceraldehyde-derived advanced glycation end products (AGEs) in patients with type 2 diabetes.

Authors:  Miwako Tsunosue; Naomi Mashiko; Yhukou Ohta; Yoshito Matsuo; Kouichi Ueda; Masayuki Ninomiya; Sho-ichi Tanaka; Masaru Hoshiko; Yasutsugu Yoshiyama; Masayoshi Takeuchi; Shin-ichiro Ueda; Sho-ichi Yamagishi
Journal:  Clin Exp Med       Date:  2009-10-16       Impact factor: 3.984

3.  Atorvastatin exerts its anti-atherosclerotic effects by targeting the receptor for advanced glycation end products.

Authors:  Bo Feng; Lei Xu; Hua Wang; Xinfeng Yan; Junli Xue; Fengjing Liu; Ji-Fan Hu
Journal:  Biochim Biophys Acta       Date:  2011-05-30

4.  Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH.

Authors:  Yuki Kimura; Hideyuki Hyogo; Sho-ichi Yamagishi; Masayoshi Takeuchi; Tomokazu Ishitobi; Yoshitaka Nabeshima; Koji Arihiro; Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2010-01-30       Impact factor: 7.527

5.  Involvement of TAGE-RAGE System in the Pathogenesis of Diabetic Retinopathy.

Authors:  Masayoshi Takeuchi; Jun-Ichi Takino; Sho-Ichi Yamagishi
Journal:  J Ophthalmol       Date:  2010-06-22       Impact factor: 1.909

Review 6.  Statins for the primary prevention of cardiovascular disease.

Authors:  Fiona Taylor; Mark D Huffman; Ana Filipa Macedo; Theresa H M Moore; Margaret Burke; George Davey Smith; Kirsten Ward; Shah Ebrahim
Journal:  Cochrane Database Syst Rev       Date:  2013-01-31

7.  Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes.

Authors:  Sho-Ichi Yamagishi; Nobutaka Nakamura; Mika Suematsu; Kuniyoshi Kaseda; Takanori Matsui
Journal:  Mol Med       Date:  2015-10-27       Impact factor: 6.354

Review 8.  Relationship of Advanced Glycation End Products With Cardiovascular Disease in Menopausal Women.

Authors:  Magdalena Pertynska-Marczewska; Zaher Merhi
Journal:  Reprod Sci       Date:  2014-09-16       Impact factor: 3.060

9.  Diabetic Kidney Disease.

Authors:  Victoria E Bouhairie; Janet B McGill
Journal:  Mo Med       Date:  2016 Sep-Oct

10.  Atorvastatin reduces proteinuria in non-diabetic chronic kidney disease patients partly via lowering serum levels of advanced glycation end products (AGEs).

Authors:  Tsukasa Nakamura; Eiichi Sato; Nobuharu Fujiwara; Yasuhiro Kawagoe; Masayoshi Takeuchi; Sayaka Maeda; Sho-ichi Yamagishi
Journal:  Oxid Med Cell Longev       Date:  2010-09-01       Impact factor: 6.543
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.